dpp 4 inhibitor glp 1 agonist DPP4 Mechanism of Action – My Endo Consult DPP-4 Inhibitors and the Quest

Tirzepatides 12.12% forecast CAGR reflects its dual receptor mechanism and superior weight-loss performance, with COFEPRIS granting an obesity label in 2024

doi: 10.1161/circulationaha.107.739938 83 BoseAKMocanuMMCarrRDYellonDM

When BMI and comorbidity thresholds are met for anti obesity pharmacotherapy, GLP-1 agonists are recommended as first line or preferred pharmacologic options because of superior weight loss efficacy and cardiometabolic benefit

Side Effects Although these medications are generally well tolerated, they can lead to uncomfortable side effects

Adjudicated four-component major adverse cardiovascular event (MACE-4 events

Another study showed that the impact of tirzepatide on weight loss was greater than semaglutide in adults who are overweight or obese, demonstrating different effects in comparison to the breast cancer population [90]